Acromegaly

Full Guideline: Acromegaly: An Endocrine Society Clinical Practice Guideline
JCEM November 2014

Laurence Katznelson, Edward R. Laws, Jr, Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, John A. H. Wass

Objective:

The aim was to formulate clinical practice guidelines for acromegaly.

Background:

Acromegaly is a chronic disorder caused by GH hypersecretion. GH circulates and stimulates production of IGF-1 from the liver and systemic tissues; IGF-1 in large part mediates the somatic and metabolic effects of GH. Hypersecretion of GH leads to excess production of IGF-1, leading to a multisystem disease characterized by somatic overgrowth, multiple comorbidities, premature mortality, and physical disfigurement. A multidisciplinary approach is critical for the management of acromegaly.

Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including:

  • the appropriate biochemical assessment,
  • a therapeutic algorithm, including use of medical monotherapy or combination therapy,
  • and management during pregnancy.

arrow Read the Full Guideline